Accessibility Menu
Antigenics logo

Antigenics(OTC) ANTI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-100%
1 Year-98%
1 Month+100%
$0.00
+0.00%
+0.00Today
Antigenics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-14
Antigenics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+100%USD 0.002025-05-16
1 month+100%USD 0.002025-05-16
3 month+100%USD 0.002025-05-16
Year to date+100%USD 0.002025-05-16
1 year-98%USD 0.002024-12-12
3 year+100%USD 0.002023-05-08
5 year-99.97%USD 0.012021-05-12
Since inception-100%USD 0.051996-02-15

Antigenics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

9.33 (High)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

ANTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Antigenics

Antigenics, Inc. is a biotechnology company based in Huntingdon Valley, Pennsylvania. The company focuses on developing innovative therapies in the healthcare sector, aiming to address unmet medical needs.

Products and Services
  • Development of novel therapeutic agents
  • Focus on biotechnology solutions for healthcare
  • Research and development in immunotherapy
Growth Outlook
  • Potential for significant advancements in immunotherapy
  • Strategic focus on addressing unmet medical needs
  • Collaboration opportunities within the biotechnology sector
Financial Highlights
  • Recent stock price range between 0.000007 and 0.00001
  • Volume of shares traded recently at 3000
  • Market capitalization currently at zero, indicating growth potential
Antigenics, Inc. operates in a dynamic sector with a focus on innovative solutions. The company's commitment to research and development positions it well for future growth, particularly in immunotherapy. The recent stock price movements and trading volume suggest a level of interest that may indicate potential for future investment opportunities. With no current market capitalization, the company presents a unique scenario for investors looking for emerging biotechnology firms.
AI Generated • Aug 24, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Lexington, MA 02421-7305, US

ANTI Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

10.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Antigenics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$218.54-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.36-0.06%
INTCIntel
$88.79-0.01%
NUNu Holdings
$14.49-0.00%

Questions About ANTI

What is the current price of Antigenics?

Antigenics is trading at $0.00 per share.

What is the 52-week range for Antigenics?

Over the past 52 weeks, Antigenics has traded between $0.00 and $0.00.

How much debt does Antigenics have?

Antigenics total debt is unavailable.

How much cash does Antigenics have on hand?

Antigenics does not have cash on hand data available.

What is Antigenics’s dividend yield?

Antigenics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services